ProTcell
Immune reconstitution in Severe Combined Immunodeficiency (SCID)
Key Facts
About Smart Immune
Smart Immune is a clinical-stage biotech pioneering a next-generation cell therapy platform to address the critical unmet need of delayed immune reconstitution. Its lead program, ProTcell, is an ex vivo generated T-cell progenitor product derived from a patient's own stem cells, designed to rapidly rebuild a complete and functional T-cell repertoire post-transplant. The technology holds promise for improving outcomes in hematopoietic stem cell transplantation (HSCT) for blood cancers and could be applied to treat severe viral infections and primary immunodeficiencies. Backed by venture capital and strategic partnerships, the company is advancing its lead asset into clinical trials.
View full company profileAbout Smart Immune
Smart Immune is a clinical-stage biotech pioneering a next-generation cell therapy platform to address the critical unmet need of delayed immune reconstitution. Its lead program, ProTcell, is an ex vivo generated T-cell progenitor product derived from a patient's own stem cells, designed to rapidly rebuild a complete and functional T-cell repertoire post-transplant. The technology holds promise for improving outcomes in hematopoietic stem cell transplantation (HSCT) for blood cancers and could be applied to treat severe viral infections and primary immunodeficiencies. Backed by venture capital and strategic partnerships, the company is advancing its lead asset into clinical trials.
View full company profile